Last reviewed · How we verify
NCT04090463: PancFORT
IORT on Borderline Resectable Pancreatic Cancer
Phase 2 trial testing Intraoperative radiotherapy in Borderline Resectable Pancreatic Cancer in 100 participants. Suspended.
30 October 2027
Quick facts
| Lead sponsor | Universita di Verona |
|---|---|
| Phase | Phase 2 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 October 2019 |
| Primary completion | 30 October 2027 |
| Estimated completion | 30 December 2027 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Intraoperative radiotherapy
Conditions studied
- Borderline Resectable Pancreatic Cancer — all drugs for Borderline Resectable Pancreatic Cancer →
Sponsor
Universita di Verona — full company profile →
Who can join
Adults 18 to 80, any sex, with Borderline Resectable Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after FOLOFIRINOX-base chemotherapy, and SBRT, increases the 3-year survival rate. A total of 101 patients will be enrolled, and these patients will receive IORT of 10 to 20 Gy, according to the resection status (to the tumor bed after resection, or to the tumor in situ in case of non-resection).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration.
Burkoň P, Trna J, Slávik M, Němeček R, et al · · 2022 · cited 24× · PMID 36289742 · DOI 10.3390/biomedicines10102480 -
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
Paiella S, Malleo G, Simoni N, Micera R, et al · · 2021 · cited 5× · PMID 33593311 · DOI 10.1186/s12885-021-07877-7 -
Intraoperative Radiation for Pancreatic Cancer.
Elguindy A, Blakaj D, Grecula J, Miller ED. · · 2025 · PMID 40935440 · DOI 10.1016/j.semradonc.2025.07.008
Verify or expand the search:
- PubMed search for NCT04090463
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intraoperative radiotherapy
Trials testing the same drug.
- NCT04088435 — Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer · terminated
Other recruiting trials for Borderline Resectable Pancreatic Cancer
Currently open trials in the same condition.
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT06387810 — Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable P · Phase 2 · recruiting
Other Universita di Verona trials
Trials by the same sponsor.
- NCT07393919 — Discontination of Antidepressants in Remitted Depression · Phase 4 · not yet recruiting
- NCT07042724 — Exercise and Nutrition on Early-stage NSCLC Outcomes: the STARLighT Study · NA · recruiting
- NCT07129954 — Fear of Falling in Muscular Dystrophy · NA · recruiting
- NCT07119827 — Personality Traits as a Variable in the Recovery of Patients With Acquired Brain Injury · recruiting
- NCT07209306 — WHO Psychological Interventions for Mental Health Outcomes in Migrants Resettled in Italy: the ADVANCE Trial · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04090463 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universita di Verona
- Last refreshed: 7 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04090463.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing